Viral Infections

CDC retained prior influenza vaccine recommendations for 2026–2027 and detailed vaccine selection, timing, dosing, and precautions.

In an emulated trial of 56,652 matched pairs with COPD, vaccination was associated with a 39% lower hazard of hospitalized influenza.

A systematic review of 155 studies found COVID-19 vaccines reduced severe outcomes across age and risk groups without new safety signals.

A prespecified DAN-RSV trial analysis found RSVpreF reduced RSV-related hospitalization regardless of heart failure status.

The FDA approved an mRNA-based influenza vaccine mFLUSIVA for adults aged 50 years and older, with accelerated approval applying to adults aged 65 years and older.

In two phase 3, double-blind, placebo-controlled trials of adults with noncirrhotic chronic hepatitis B virus infection receiving stable nucleoside or nucleotide analog therapy, 24 weeks of bepirovirsen...

FDA approval gives physicians the first authorized treatment option for adults with chronic hepatitis delta virus infection.

In a large multicountry trial, researchers evaluated whether an integrase inhibitor–based regimen offers comparable or superior treatment outcomes to a boosted protease inhibitor regimen in adults with...

In this respiratory disease roundup, researchers report on the efficacy of nirmatrelvir-ritonavir for treating Long COVID, the CDC updates recommendations on “triple threat” vaccines for respiratory virus...

In a cohort study, researchers observed a significant decrease in incident reinfection among patients with Hepatitis C who received increased follow-up after achieving sustained virologic response.